22-24 October, 2018
Frankfurt, Germany

The Industry Definitive Forum
for Actionable Insights

Speakers

Expand/Collapse

Adil Mardinoglu
Assistant Professor of Systems Biology
Royal Institute of Technology (KTH)

Dr. Adil Mardinoglu is an expert in the field of Systems Biology and Bioinformatics. He received his Bachelor’s degree from Istanbul Technical University, Turkey in Electronic and Telecommunication Engineering and his Ph.D. from Waterford Institute of Technology, Ireland in drug targeting applications. He worked as a postdoctoral researcher at Trinity College Dublin, Ireland and Chalmers University of Technology, Gothenburg, Sweden. His recent research activities include the generation of the context specific genome-scale metabolic models for healthy human cell-types e.g. adipocytes, hepatocytes and myocytes as well as certain types of cancer e.g. liver cancer. He employed the reconstructed comprehensive models for revealing the molecular mechanisms of obesity associated diseases as well as for discovery of the novel biomarkers and drug targets. He also reconstructed personalized and population based models for liver cancer patients in order to identify anticancer drug targets that can inhibit the growth of, or kill tumors

Pre Conference - Workshop A

Monday, October 22, 2018

10.00 | Systems Biology in NASH: Approaches & Applications

Elias Papatheodorou
Chief Executive Officer
Genkyotex

Day Two

Wednesday, October 24, 2018

09.30 | Targeting Multiple Fibrogenic Pathways with the NOX1/4 Inhibitor GKT831

Marcin Krawczyk

Saarland University Medical Center

Day One

Tuesday, October 23, 2018

14.15 | Addressing Heterogeneity & the Role of Genetics in NASH Patient Populations

Peter Traber
Partner
Alarita Consulting

Day Two

Wednesday, October 24, 2018

13.30 | Therapeutic Approaches to Cirrhotic Versus Non-Cirrhotic NASH

Pnina Fishman
Chief Executive Officer
Can-Fite BioPharma

Day Two

Wednesday, October 24, 2018

11.00 | The Polypharmacological Anti-NASH Effects of Namodenoson Are Mediated via De-Regulation of the Wnt/β-catenin Pathway

Gregory Michelotti
Associate Director, Discovery & Translational Sciences
Metabolon

Day One

Tuesday, October 23, 2018

13.00 | Metabolomic Profiling to Identify Molecular Determinants of Liver Disease

Jonathan Riek
Vice President, Musculoskeletal & Metabolic Imaging
BioTel Research

Day One

Tuesday, October 23, 2018

14.45 | Imaging for NASH Clinical Trials

Aimo Kannt
Cluster Head Comorbidities & Complications of Diabetes
Sanofi

 

Day One

Tuesday, October 23, 2018

11.30  | NASH as a Component of Systemic Cardiometabolic Disease

Andreas Geier
Head of Hepatology
University of Wurzburg

Day Two

Wednesday, October 24, 2018

14.00 | The Reality of Clinical Diagnostics & Treatment

Bill Esler
Senior Director
Pfizer

William (Bill) Esler, PhD is a Senior Director in the Internal Medicine Research Unit at Pfizer.  Bill is a Research Project Leader and is responsible for leading drug discovery programs from early discovery stages through clinical Proof of Concept.  While at Pfizer, he has led multiple drug discovery and development projects principally in the areas of NASH and type 2 diabetes mellitus.  Bill also contributes to Pfizer’s integrated NASH disease area strategy. Bill is a broadly trained scientist with expertise in drug discovery and development and in metabolic diseases and NASH.   He received his undergraduate training in Chemistry at Trinity College in Hartford CT and earned his PhD in Biological Chemistry and Molecular Pharmacology from Harvard University in Cambridge MA.  He subsequently undertook postdoctoral training at Harvard Medical School and Brigham and Women’s Hospital in Boston MA. Bill joined Pfizer in 2007.  Prior to his current role as project leader, Bill oversaw a research laboratory focused on metabolic disease drug discovery.  

Day One

Tuesday, October 23, 2018

09.30 | Acetyl-CoA Carboxylase Inhibitors from Bench to Bedside & Back Again

Claus Kremoser
Chief Executive Officer
Phenex Pharmaceuticals

Dr Claus Kremoser is the Chief Executive Officer of Phenex Pharmaceuticals AG. Phenex is a drug discovery company that focuses on the identification and early development of small molecule drugs that target novel receptors. Claus is also a Member of the Board for Avelas Biosciences and Cardior GmbH and is involved with BIO Deutschland and BioRN Network. Prior to this Claus has held positions of responsibility at LION Bioscience and Ernst & Young. Claus received his PhD in Molecular Developmental Neurobiology from the Max-Plank Institute of Developmental Biology.

Day Two

Wednesday, October 24, 2018

15.00 | How to Develop a Differentiated FXR Agonist that Avoids the Side Effects of 1st Generation FXR Drugs

David Fraser
Chief Scientific Officer
NorthSea Therapeutics

Dr. David A. Fraser, a co-founder of NorthSea Therapeutics B.V., formerly worked as Group Lead Discovery R&D at Pronova Biopharma AS, part of BASF. Prior to joining Pronova in 2008, he worked as a post-doctoral fellow at Oslo University Hospital, primarily focused on diabetic microvascular complications. He also held a position as Research Officer at Menzies School of Health Research, Darwin, Australia in addition to posts at Nycomed (Denmark) and Aventis Pharma (Norway). He obtained his Ph.D from the University of Oslo, Norway where he studied immune and endocrine responses to acute starvation in patients with rheumatoid arthritis and holds an MSc (with distinction) in Human Nutrition and Metabolism from the University of Aberdeen, Scotland.​​

Day Two

Wednesday, October 24, 2018

11.30 | Anti-Inflammatory & Anti-Fibrotic Effects of Icosabutate, a Structurally Engineered Fatty Acid, in Differentiated Rodent NASH Models

Dimitar Tonev
Honorary Consultant
HCV Research UK

Dimitar is a pharmaceutical physician with 20 years of drug and diagnostics development across the universe of chronic liver diseases. He acts as Medical Director for Humedics, Perspectum Diagnostics and has previously held the role of Medical Director at Promethera Biosciences and Regional Medical Director at Intercept Pharmaceuticals.

Pre Conference - Workshop B

Monday, October 22, 2018

14.00 | Addressing Challenges Relating to Non-Invasive Technology Used for the Identification of NAFLD/NASH

Donny Wong
Global Analytics & Insight Lead, CVRM Early Assets
AstraZeneca

 

Eric Hughes
Head of Global Development Franchise, Immunology & Dermatology
Novartis

 

Day Two

Wednesday, October 24, 2018

16.00 | Chair’s Closing Remarks

08.50 | Chair’s Opening Remarks

Gabriel Baverel
President & Chief Executive Officer
Metabolys

Gabriel Baverel is a DVM by training. He also holds a PhD in biochemistry and did a post-doc under Professor H.A. Krebs. He is a former professor of physiology in the Laennec faculty of medicine in Lyon and the former  head of an INSERM research unit (Metabolomics and Metabolic Diseases). In 2009, he founded Metabolys, a biopharmaceutical company developing drug candidates for treating metabolic diseases.  

Day Two

Wednesday, October 24, 2018

09.00 | MTBL0036, a New Anti-NASH & Anti-Fibrotic Compound with a Mitochondrial Molecular Target

Henning Grønbæk
Professor Internal Medicine & Hepatology
Aarhus University

Professor in Internal Medicine & Hepatology, Aarhus University Hospital, Aarhus, Denmark. My research has focused om macrophages and macrophage activation markers in inflammatory liver diseases and with a key interest in clinical and experimental NASH.  

Day One

Tuesday, October 23, 2018

15.45 | The Role of Macrophages in Non-Alcoholic Fatty Liver Disease - From Biomarkers to Treatment Targets

Nikolai Naoumov
Executive Director, Hepatology Science & Innovation
Novartis

Nikolai Naoumov works at Novartis Global Drug Development as Executive Director for Hepatology Science and Innovation, based in Basel, Switzerland. His focus is on developing new therapies for patients with liver diseases especially NASH, autoimmune diseases, liver fibrosis and complications of cirrhosis.  In addition to his work at Novartis Global, Nikolai is also Honorary Scientific Advisor to the Foundation for Liver Research in the UK and Board member of the Liver Foundation in Switzerland. Before joining Novartis in 2007, Nikolai was a tenured Professor of Hepatology at University College London and Consultant Hepatologist at University College London Hospitals. Nikolai has been involved in the development and evaluation of many of the new treatments for patients with liver diseases, initially at the Institute of Liver Studies, King’s College Hospital in London and subsequently at the Institute of Hepatology, University College London. Nikolai has more than 200 publications in the fields of liver immunology, treatment of viral hepatitis and liver transplantation. He is Fellow of both the Royal College of Physicians (London) and the Royal College of Pathologists in the UK, and member of the Association of Physicians of Great Britain and Northern Ireland. He joined EASL in 1987, served as member of the EASL Scientific Committee (1991-1994), and was elected as a Fellow of the American Association for the Study of Liver Diseases (AASLD).  

Day Two

Wednesday, October 24, 2018

10.00 | Targeting Multiple Pathways in NASH – Clinical Perspectives for Combination Therapies

Rebecca Taub
Chief Medical Officer, Executive Vice President Research & Development
Madrigal Pharmaceuticals

Day Two

Wednesday, October 24, 2018

15.30 | Showcasing the Clinical Development of MGL3196

Richard Lee
Director
Ionis Pharmaceuticals

Richard Lee is a Director in the Cardio/Metabolic/Renal section, which is part of the Antisense Drug Discovery group at Ionis Pharmaceuticals. He received his PhD training in the laboratory of Dr. Larry Rudel at Wake Forest University, followed by a postdoctoral fellowship in Dr. Peter Edwards laboratory at the University of California Los Angeles which focused on the characterization of key genes in lipoprotein metabolism. Dr. Lee then transitioned to Ionis Pharmaceuticals to help advance therapy for a number of cardio-metabolic diseases, particularly treatments for underserved cardiovascular risk factors, using antisense technology. Over the last 10 years Dr. Lee has made key contributions in understanding the role of various genetically validated lipid risk factors, such as apoB, apoC-III, Lp(a) and angiopoietin-like 3 protein. The most advanced drug, an antisense inhibitor to apoB-100 (mipomersen-KynamroTM), the principal apolipoprotein for LDL-cholesterol, was approved by the FDA in January 2013 for the treatment of homozygous familial hypercholesterolemia (HoFH). He has also helped determine the the preclinical mechanisms of action of volanosorsen, a human apoC-III antisense inhibitor, which recently completed a successful Phase 3 trial in familial chylomicronemia syndrome, and IONIS-ANGPTL3-LRx, which is currently entering Phase 2 trials for dyslipidemia/metabolic syndrome.  His current area of research focuses on a number of novel targets for the treatment of metabolic diseases.

Sebastien Bolze
Chief Scientific Officer
Poxel Pharmaceuticals

Sébastien Bolze has broad experience in drug development from discovery screening to proof of concept clinical trials. Before co-founding Poxel in 2009, Dr. Bolze was global head of the preclinical candidate selection unit at Solvay Pharmaceuticals, a multidisciplinary unit providing support to research projects from optimization of validated hits to delivery of candidates for preclinical development. From 2003 to 2006, he was executive head of the ADME department at Fournier Pharma. He acquired strong organizational and managerial experience in drug development projects particularly in the metabolic disease area. Dr. Bolze has also co-authored numerous research publications and posters. Dr. Bolze is a Pharmacist and holds a Ph.D. in Pharmacokinetics and Drug Metabolism from the University of Lyon I (France).  

Day Two

Wednesday, October 24, 2018

12.00 | PXL770, a Direct AMP Kinase Activator, for the Treatment of NASH

Sophie Mégnien
Chief Medical Officer
Genfit

After studying in several countries, including the United States, Sophie Mégnien obtained her degree in Medicine from the University of Paris VI. She is an expert in the clinical development of cardiometabolic diseases (hypercholesterolemia, diabetes) and their vascular (atherosclerosis) and hepatic complications. She completed her internship in the field of clinical trial monitoring. Since then, she has held a number of posts as Project Manager in the R&D departments of various international pharmaceutical companies such as Smithkline Beecham, Glaxo Wellcome and Bayer. After ten years as a Project Manager, Sophie Mégnien became a consultant in Quality Management and Procedures at Sunnikan Consulting before joining Naturalpha, a company specializing in the coordination of clinical projects in the cardiovascular, metabolic and nutrition fields. Sophie Mégnien is currently Chief Medical Officer at GENFIT.

Day One

Tuesday, October 23, 2018

16.45 | Chair’s Closing Remarks

09.00 | Regulatory Landscape in NASH

08.50 | Chair’s Opening Remarks

Stephen Rossi
Senior Director, Clinical Development & Medical Affairs
NGM Biopharmaceuticals

Suneil Hosmane
Executive Vice President – Strategic Development
Genfit

Day One

Tuesday, October 23, 2018

16.15 | Developing an In Vitro Diagnostic Test (IVD) In Parallel to Advancing a Drug Candidate